Clínica Baviera, S.A. (BME: CBAV)
Spain
· Delayed Price · Currency is EUR
30.90
-1.00 (-3.13%)
Dec 20, 2024, 5:35 PM CET
Clínica Baviera Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 252.47 | 227.07 | 198.45 | 173.25 | 122.63 | 124.33 | Upgrade
|
Revenue Growth (YoY) | 16.17% | 14.42% | 14.55% | 41.28% | -1.37% | 13.76% | Upgrade
|
Cost of Revenue | 136.51 | 115.1 | 96.55 | 84.05 | 64.23 | 62.39 | Upgrade
|
Gross Profit | 115.96 | 111.97 | 101.9 | 89.2 | 58.4 | 61.95 | Upgrade
|
Selling, General & Admin | 12.09 | 12.09 | 11.69 | 9.87 | 7.82 | 9.41 | Upgrade
|
Other Operating Expenses | 32.86 | 32.86 | 33.25 | 25.77 | 17.2 | 21 | Upgrade
|
Operating Expenses | 64.63 | 61.93 | 59.94 | 49.73 | 38.57 | 43.63 | Upgrade
|
Operating Income | 51.33 | 50.04 | 41.96 | 39.46 | 19.83 | 18.32 | Upgrade
|
Interest Expense | -0.28 | -0.57 | -0.42 | -0.46 | -0.54 | -0.59 | Upgrade
|
Interest & Investment Income | 0.87 | 0.15 | 0.07 | 0 | 0.01 | 0 | Upgrade
|
Earnings From Equity Investments | -0.01 | -0.01 | -0.06 | -0.03 | 0.2 | 0.08 | Upgrade
|
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0 | -0 | - | - | Upgrade
|
Other Non Operating Income (Expenses) | 0.07 | 0.07 | -0.4 | -0.04 | -0 | -0.01 | Upgrade
|
EBT Excluding Unusual Items | 51.98 | 49.68 | 41.15 | 38.93 | 19.51 | 17.79 | Upgrade
|
Asset Writedown | -0.03 | -0.03 | -0.47 | -0.03 | - | - | Upgrade
|
Other Unusual Items | - | - | - | - | 0.68 | - | Upgrade
|
Pretax Income | 51.95 | 49.65 | 40.68 | 38.9 | 20.19 | 17.79 | Upgrade
|
Income Tax Expense | 14.11 | 12.92 | 10.53 | 10.97 | 6.05 | 4.89 | Upgrade
|
Earnings From Continuing Operations | 37.84 | 36.73 | 30.15 | 27.93 | 14.13 | 12.9 | Upgrade
|
Net Income to Company | 37.84 | 36.73 | 30.15 | 27.93 | 14.13 | 12.9 | Upgrade
|
Minority Interest in Earnings | -0.76 | -0.76 | -0.63 | -0.54 | -0.19 | -0.11 | Upgrade
|
Net Income | 37.07 | 35.97 | 29.52 | 27.39 | 13.94 | 12.79 | Upgrade
|
Net Income to Common | 37.07 | 35.97 | 29.52 | 27.39 | 13.94 | 12.79 | Upgrade
|
Net Income Growth | 14.90% | 21.86% | 7.77% | 96.46% | 8.97% | 8.19% | Upgrade
|
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade
|
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade
|
Shares Change (YoY) | - | -0.00% | - | 0.01% | -0.01% | -0.01% | Upgrade
|
EPS (Basic) | 2.32 | 2.21 | 1.81 | 1.68 | 0.86 | 0.78 | Upgrade
|
EPS (Diluted) | 2.32 | 2.21 | 1.81 | 1.68 | 0.86 | 0.78 | Upgrade
|
EPS Growth | - | 21.86% | 7.77% | 96.43% | 8.97% | 8.20% | Upgrade
|
Free Cash Flow | 36.37 | 35.13 | 39.35 | 36.28 | 23.64 | 16.21 | Upgrade
|
Free Cash Flow Per Share | 2.28 | 2.16 | 2.41 | 2.23 | 1.45 | 0.99 | Upgrade
|
Dividend Per Share | - | 1.570 | 1.300 | 1.030 | 0.552 | - | Upgrade
|
Dividend Growth | - | 20.77% | 26.21% | 86.59% | - | - | Upgrade
|
Gross Margin | 45.93% | 49.31% | 51.35% | 51.49% | 47.62% | 49.82% | Upgrade
|
Operating Margin | 20.33% | 22.04% | 21.14% | 22.78% | 16.17% | 14.73% | Upgrade
|
Profit Margin | 14.68% | 15.84% | 14.87% | 15.81% | 11.37% | 10.29% | Upgrade
|
Free Cash Flow Margin | 14.41% | 15.47% | 19.83% | 20.94% | 19.28% | 13.04% | Upgrade
|
EBITDA | 70.5 | 66.5 | 56.76 | 53.35 | 33.21 | 31.34 | Upgrade
|
EBITDA Margin | 27.92% | 29.29% | 28.60% | 30.80% | 27.08% | 25.21% | Upgrade
|
D&A For EBITDA | 19.17 | 16.46 | 14.8 | 13.89 | 13.38 | 13.02 | Upgrade
|
EBIT | 51.33 | 50.04 | 41.96 | 39.46 | 19.83 | 18.32 | Upgrade
|
EBIT Margin | 20.33% | 22.04% | 21.14% | 22.78% | 16.17% | 14.73% | Upgrade
|
Effective Tax Rate | 27.17% | 26.02% | 25.89% | 28.20% | 29.99% | 27.47% | Upgrade
|
Advertising Expenses | - | 10.31 | 9.86 | 8.42 | 5.79 | 8.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.